Scarica l'app Stockscreener
20.34
3.78%
-0.80
Dopo l'orario di chiusura:
20.41
0.07
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance
Will Sarepta Therapeutics Inc. stock maintain momentum in 2025Exit Point & Technical Buy Zone Confirmations - Улправда
Sarepta Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Low Entry Investment Portfolio - earlytimes.in
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Applauds Addition of Duchenne Muscular Dystrophy to the U.S. Recommended Uniform Screening Panel (RUSP) - Sarepta Therapeutics
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Argenx Se (ARGX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.3%Still a Buy? - MarketBeat
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025 - ts2.tech
Why Sarepta Therapeutics Stock is Gaining Attention - TipRanks
Sarepta Therapeutics (SRPT) Rises as HHS Expands Newborn Screeni - GuruFocus
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. - CBS News
683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownHere's What Happened - MarketBeat
Sarepta Therapeutics Refinances Convertible Senior Notes - The Globe and Mail
Sarepta CEO given first equity award in 8 years - The Business Journals
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Sarepta Therapeutics refinances convertible senior notes - MSN
Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing - Investing.com
Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing By Investing.com - Investing.com UK
Sarepta Therapeutics stock falls after debt exchange announcement By Investing.com - Investing.com South Africa
Sarepta Therapeutics stock falls after debt exchange announcement - Investing.com
Why Is SRPT Stock Falling Today? - Stocktwits
Sector Update: Health Care Stocks Mixed Premarket Thursday - marketscreener.com
Sarepta dips after announcing debt refinancing - TradingView
Sarepta Therapeutics stock falls after refinancing of convertible notes By Investing.com - Investing.com South Africa
Sarepta Therapeutics stock falls after refinancing of convertible notes - Investing.com
Sarepta to refinance $291M of existing notes due 2027 - MSN
Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027 - marketscreener.com
Sarepta Therapeutics announces refinancing of approximately $291 million of 1.25% convertible senior notes due 2027 - marketscreener.com
Sarepta Therapeutics Announces Refinancing Of Approximately $291 Million Of 1.25% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Sarepta to exchange $291.4 million in convertible notes - Investing.com
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire
CFO Wong Surrenders 158 Of Sarepta Therapeutics Inc [SRPT] - TradingView — Track All Markets
Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says - marketscreener.com
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
Sarepta Therapeutics, Inc. $SRPT Shares Bought by Federated Hermes Inc. - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq Index Tracks Biotech Advancements - Kalkine Media
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound - Yahoo Finance
Is Sarepta Therapeutics a Bargain After Recent Share Rebound and DCF Valuation Check? - Yahoo Finance
Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off - Finimize
Wedbush Says Sarepta Selloff “Overdone” - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpWhat's Next? - MarketBeat
Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says - marketscreener.com
Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential - GuruFocus
Sarepta a new outperform at Wedbush as selloff overdone - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wedbush - MarketBeat
SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT S - GuruFocus
Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating - Investing.com
Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating By Investing.com - Investing.com UK
Sarepta (SRPT) Stock Outlook: Wedbush Predicts Potential Growth - GuruFocus
Regenerative Medicine Market 2025-2033: Key Trends, Research - openPR.com
New York State Common Retirement Fund Sells 7,923,000 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (SRPT) Is Up 6.8% After FDA Clears Cohort 8 Dosing in ENDEAVOR Trial - simplywall.st
Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug - Citeline News & Insights
Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram - Investing.com Nigeria
Why Is Dyne Therapeutics Stock Surging Monday?Dyne Therapeutics (NASDAQ:DYN), Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Dyne readies FDA push after DMD exon 51 med excels in trial - Fierce Biotech
0.31%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):